Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure. - Wikidata - wikimedia - TriplyDB

Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.

Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.

http://www.wikidata.org/entity/Q31956589

about

Role of endothelin in cardiovascular disease Ambrisentan, a non-peptide endothelin receptor antagonist Endothelin receptor antagonists and cerebral vasospasm: an update.Endothelin receptor antagonists and cardiovascular diseases of aging.Endothelin antagonists and heart failure.Endothelin-1 and endothelin receptor antagonists as potential cardiovascular therapeutic agents.Endothelin receptor antagonists in cardiology clinical trials.Present and future pharmacotherapy for heart failure.Heart failure in 10 years time: focus on pharmacological treatment.Endothelin and endothelin receptor antagonists in heart failure.The therapeutic potential of endothelin-1 receptor antagonists and endothelin-converting enzyme inhibitors on the cardiovascular system.New therapies for the management of acute heart failure.Endothelin.Role of endothelins in congestive heart failure.Acute decompensated heart failure: a contemporary approach to pharmacotherapeutic management.Drug therapy in chronic heart failure.Tezosentan in the treatment of acute heart failure.Combination pharmacologic therapies for heart failure: what next after angiotensin-converting enzyme inhibitors and beta-blockers?Ion channelopathy and hyperphosphorylation contributing to cardiac arrhythmias.The endothelin system as a therapeutic target in cardiovascular disease: great expectations or bleak house?Future pharmacologic agents for treatment of heart failure in children.Aldosterone breakthrough during RAS blockade: a role for endothelins and their antagonists?Endothelin-1, aging and hypertension.Left ventricular dysfunction with pulmonary hypertension: part 2: prognosis, noninvasive evaluation, treatment, and future research.The science of endothelin-1 and endothelin receptor antagonists in the management of pulmonary arterial hypertension: current understanding and future studies.Emerging therapies for heart failure: renal mechanisms and effects.Pulmonary vasodilation in acute and chronic heart failure: empiricism and evidence.Endothelin receptor polymorphisms in the cardiovascular system: potential implications for therapy and screening.Pathophysiology and potential treatments of pulmonary hypertension due to systolic left heart failure.Echocardiographic estimation of pulmonary capillary wedge pressure using the combination of diastolic annular and mitral inflow velocities.Emerging therapies for heart failure.Increased mortality with elevated plasma endothelin-1 in acute heart failure: an ASCEND-HF biomarker substudy.Management of acute subdural hematoma in a patient with portopulmonary hypertension on prostanoid therapy.The role of endothelin converting enzyme inhibition during group B streptococcus-induced pulmonary hypertension in newborn piglets.Acute cardiopulmonary effects of a dual-endothelin receptor antagonist on oleic acid-induced pulmonary arterial hypertension in dogs.Cardiac effects of endothelin receptor antagonism in endotoxemic pigs.

P2860

Q28216230-120A91A4-B23A-4E95-A889-2A46274430F6 Q28260732-52B510C7-E05F-4E1D-BFBA-490B03D5480A Q30310232-7689AD5F-17BC-43F3-B0AF-09EFFAD9ADD5 Q34289891-C3C90040-62CD-4EBA-876C-C44EE01CFF49 Q34492848-19EBFCF9-6A53-48FF-9546-476F20385146 Q34496108-BF81F90F-5204-40D5-B269-60DF5B206A32 Q34544685-48BCF442-F334-401D-BBEF-5D8CD70FF2A6 Q34706912-96D49382-31FB-4B75-91B9-E777776DA44D Q34817094-53E105F9-9402-4D16-BA9B-F027D046D08B Q34943424-1D9529B4-DF08-4F8F-AC4D-A4A17B32F167 Q35001002-BAD4432D-8DEB-4000-8481-61FA9F526762 Q35105845-A40935D3-787C-4276-B43A-8225DFB8E5AB Q35120667-0F045DD1-3A87-4C42-A21D-8110DEAE884D Q35168419-DDC5EDD4-098C-4808-983A-641FE6B57014 Q35200873-ADF90F2C-C92A-4D51-8544-DA3CEBF8157E Q35518236-CFBDE0E7-C61D-4359-951B-2EB72F208DB3 Q35590982-8309A18C-4680-4A3D-A5A9-222902D26D57 Q36203160-6478155E-C628-41A0-AC29-70B791B911FE Q36204496-34F6CB0E-12DA-4B82-9B03-0145EC69BF2F Q36510011-0108721A-5837-437B-9372-1B884728E546 Q36577692-989D5295-BABC-4B8D-9338-B78E004E4A4C Q36674362-9F774204-1D83-4CE2-A8BC-4743763AC2A1 Q36726832-E9D52770-FEDE-4A76-B9D8-2AD1A6233F6C Q36868978-63BCE0AF-136A-4701-833D-2DD86CE8E311 Q37428038-5A1FE28D-AC27-46B0-8491-7925084CD41F Q37783956-2F6AA947-EF64-4E5E-BDD6-E4598E983731 Q37873778-DFBC6F3D-A2C6-485B-BE92-E0A677A46B3A Q38191192-A198AB0E-FA07-474A-96BF-B8B94C7C0D79 Q38202309-A88B20FD-BBC4-48D5-B269-DE3080BD5549 Q39399607-736F9AC3-F6FF-4DBB-806F-36C490D20526 Q40409363-F99A4E73-3CE0-44EF-996B-600E149BA233 Q41054061-FEA4813D-4C3A-4236-96C6-134B5A5904D4 Q41339390-FE83C06B-F1F6-47CC-A155-E448D0288501 Q44467182-669B678A-227E-4CBA-A910-59FF8EBE2ACE Q44766880-82BFAE61-8B82-4915-AB4E-40D0B9A85A94 Q54444024-3F0BA4C1-4CE8-4751-B2CF-1EF5004FD2F8

P2860

Hemodynamic effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients with class III to IV congestive heart failure.

http://www.wikidata.org/entity/Q31956589

description

2001 nî lūn-bûn

@nan

2001 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2001 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2001年の論文

@ja

2001年論文

@yue

2001年論文

@zh-hant

2001年論文

@zh-hk

2001年論文

@zh-mo

2001年論文

@zh-tw

2001年论文

@wuu

name

Hemodynamic effects of tezosen ...... o IV congestive heart failure.

@ast

Hemodynamic effects of tezosen ...... o IV congestive heart failure.

@en

type

label

Hemodynamic effects of tezosen ...... o IV congestive heart failure.

@ast

Hemodynamic effects of tezosen ...... o IV congestive heart failure.

@en

prefLabel

Hemodynamic effects of tezosen ...... o IV congestive heart failure.

@ast

Hemodynamic effects of tezosen ...... o IV congestive heart failure.

@en

P1433

Q31956589-96641EA2-1A7D-42F6-8CB6-53B54B21D057

P1476

Q31956589-05892383-071B-42E1-8250-C202BB90C1A5

P2093

Q31956589-021B14E7-0894-48FB-88B2-0A67DDD7FD65

Q31956589-2A594011-8406-4979-8210-A4C886CA29B1

Q31956589-52833A4B-9C2A-4401-8E6C-BA070C79AD15

Q31956589-5D542AC4-267E-42E1-A10D-DE2715CBC713

Q31956589-7F48FFAA-4A2F-4C05-B9F7-7D8387A26C1C

Q31956589-9AFA0AD3-F017-4016-BED5-07435B4937B6

Q31956589-F4DD9D1D-D688-439E-BF53-7E94421F04FD

P304

Q31956589-F949850E-20E4-4085-A029-F51BCBCE364A

P31

Q31956589-E542D795-01FC-42DC-BC21-C962EEFD9B6E

P356

Q31956589-76639C46-4825-4033-83D6-A388E074D941

P407

Q31956589-B90E3C47-EB2E-4D22-832C-45C08F576DE5

P433

Q31956589-84CCBADA-1F4F-4491-BB24-705D675818FF

P478

Q31956589-10344BC4-A1F6-43FE-9A0A-B05EB84F127A

P577

Q31956589-F03F7486-D13B-4761-9EBB-AC523AD68E9F

P5875

Q31956589-712AB4DA-12D3-4487-B82C-16BBBB802993

P698

Q31956589-41B03625-1242-49BE-AF3B-356391DA8C6C

P921

Q31956589-3B64BB96-186F-401B-A2D0-0052C50D3471

Q31956589-53FC7853-DC4B-41A6-9700-76EB25619021

P356

01.CIR.103.7.973

P1433

P1476

Hemodynamic effects of tezosen ...... o IV congestive heart failure.

@en

P2093

Bozkurt B

http://www.w3.org/2001/XMLSchema#string

Durand J

http://www.w3.org/2001/XMLSchema#string

Kobrin I

http://www.w3.org/2001/XMLSchema#string

Mann DL

http://www.w3.org/2001/XMLSchema#string

Pratt CM

http://www.w3.org/2001/XMLSchema#string

Torre-Amione G

http://www.w3.org/2001/XMLSchema#string

Young JB

http://www.w3.org/2001/XMLSchema#string

P304

973-980

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1161/01.CIR.103.7.973

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

103

http://www.w3.org/2001/XMLSchema#string

P577

2001-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

285247089

http://www.w3.org/2001/XMLSchema#string

P698

11181472

http://www.w3.org/2001/XMLSchema#string

P921